Merck To Pay Up To $1.25B For Neurogenic Biotech Afferent
New Jersey-based pharmaceutical giant Merck will snap up venture capital-backed Afferent Pharmaceuticals, a California biotech developing treatments for common neurogenic conditions, in a deal worth up to $1.25 billion, including milestone...To view the full article, register now.
Already a subscriber? Click here to view full article